Results 1 to 10 of about 743,575 (143)

Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy

Frontiers in Oncology, 2022
BackgroundAlthough achieving pathological complete response (pCR) and near-pathological complete response (near-pCR) after neoadjuvant chemotherapy (NAC) in breast cancer predicts a better outcome, some patients still experience recurrence.
Xiaoyan Qian, Xiaoyan Qian, Meng Xiu, Qing Li, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Qiao Li, Shanshan Chen, Peng Yuan, Fei Ma, Binghe Xu, Pin Zhang   +13 more
doaj   +1 more source

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy

Case Reports in Oncology, 2021
A 61-year-old man was referred to our hospital due to the liver dysfunction without hepatitis B or C infection. In addition to the elevated levels of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II, a large tumor, 10.8 cm in
Hiroshi Shintani, Shoji Oura, Shinichiro Makimoto   +2 more
doaj   +1 more source

The impact of pathological complete response on survival in patients with breast cancer and occurrence in different intrinsic subtypes: A retrospective observational study

Cancer Research, Statistics, and Treatment, 2023
Background: Pathological complete response (pCR), defined as non-invasive or in situ disease in the breast and regional lymph nodes following neoadjuvant chemotherapy (NACT) predicts oncologic outcomes.
Anupama Radhakrishnan, Pritha Roy, Krishnangshu B Chowdhury, Ritam Joarder, Partha Dasgupta   +4 more
doaj   +1 more source

The role of shear wave elastography in early prediction of response to neaodjuvant chemotherapy in cases of breast cancer

The Egyptian Journal of Radiology and Nuclear Medicine, 2023
Background Breast cancer is the most common malignant tumor and the commonest cause of death in female between 35 and 55 years of age. Neoadjuvant chemotherapy (NACT) is used in large scale nowadays in management of breast cancer.
Alaa Mohamed Ahmed Elmosselhy Elmoghazy, Omina Mokhtar Nada, Manal Mohamed Refaat Beshir, Rehab Ahmed Elbadri Elhakim, Tarek Mohamed Hashem, Osman Mohamed Mansour, Amira Hamed Radwan   +6 more
doaj   +1 more source

Complete pathological response following neoadjuvant chemoradiotherapy in locally advanced colorectal carcinoma

Libri Oncologici, 2022
Background: The prognosis of rectal cancer has improved with neoadjuvant treatment for locally advanced disease. Twenty percent of patients respond to treatment with complete pathological regression, which is clinically estimated with magnetic resonance ...
Ozana Miličević, Ines Trkulja, Andrija Matijević, Loris Ćurt, Patricija Sesar, Meliha Solak, Snježana Ramić, Iva Kirac   +7 more
doaj   +1 more source

Complete Pathological Response in Stage IV Rectal Carcinoma: Proper Planning and Place is a Key

Indonesian Journal of Cancer, 2022
Introduction: Liver metastasis is frequently encountered in patients with rectal cancer; it can be synchronous or metachronous. Some selected patients can be treated with curative intent using multimodality therapy under the care of a dedicated team in a
Deep Lamichhane , Suraj Suwal, Resham Rana, Shweta Baral, Rishikesh Narayan Shrestha   +4 more
doaj   +1 more source

Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma [PDF]

, 2014
Neoadjuvant chemoradiation therapy (CRT) is increasingly the standard of care for locally advanced oesophageal cancer. A complete pathological response to CRT is associated with a favourable outcome.
Lynam-Lennon, Niamh, Maguire, Aoife, Maher, Stephen G., Muldoon, Cian, O'Sullivan, Jacintha, O’Sullivan, Jacintha, Phelan, James, Reynolds, John V.   +7 more
core   +6 more sources

Clinical-grade whole-genome sequencing and 3′ transcriptome analysis of colorectal cancer patients

Genome Medicine, 2021
Background Clinical-grade whole-genome sequencing (cWGS) has the potential to become the standard of care within the clinic because of its breadth of coverage and lack of bias towards certain regions of the genome.
Agata Stodolna, Miao He, Mahesh Vasipalli, Zoya Kingsbury, Jennifer Becq, Joanne D. Stockton, Mark P. Dilworth, Jonathan James, Toju Sillo, Daniel Blakeway, Stephen T. Ward, Tariq Ismail, Mark T. Ross, Andrew D. Beggs   +13 more
doaj   +1 more source

Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer

Northwestern Medical Journal, 2023
Aim: In this study, we aimed to investigate the factors that may have the potential to predict pathological complete response (pCR) with platinum-based neoadjuvant chemotherapy (NAC) in non-metastatic muscle-invasive bladder cancer (MIBC). Methods: Our
Zuhat Urakçı, Senar Ebinç, Sezai Tunç, Zeynep Oruç, Mehmet Küçüköner, Muhammet Ali Kaplan, Abdurrahman Işıkdoğan   +6 more
doaj   +1 more source

Evaluation of Pathological Response in Post-Neoadjuvant Chemotherapy Breast Carcinoma Specimens using Residual Cancer Burden System [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Many systems have been proposed to classify the degree of tumour response to therapy in post-neoadjuvant Chemotherapy (NACT) breast cancers. The Residual Cancer Burden (RCB) developed by MD Anderson cancer hospital is an online tool for
Lakshmi Manasa Perubhotla, Suseela Kodandapani, Sudha S Murthy   +2 more
doaj   +1 more source